Foghorn Therapeutics reported in its Q2 update progress on FHD-909 with Lilly and launched a new oral immunology and inflammation program, expanding beyond onco

BWB News TV • 2026-08-06 11:41 UTC • By Billy Odell Tucker-Robinson

Foghorn Therapeutics reported in its Q2 update progress on FHD-909 with Lilly and launched a new oral immunology and inflammation program, expanding beyond oncology and signaling a broader pipeline strategy.

Share this article

𝕏 X / Twitter Facebook LinkedIn WhatsApp

📚 More from Billy’s World

📰 Banking With Billy News All breaking financial news & market analysis 📚 Banking With Billy Books Deep-dive books on every financial story 💬 Join the Community discord.gg/VHxwmR5j4Y 🎥 Banking With Billy on YouTube Live streams & market commentary

Banking With Billy News Network — bankingwithbilly.com
Discord: discord.gg/VHxwmR5j4Y • YouTube: @BankingWithBilly